0000105770-26-000010
SEC filingWest Pharmaceutical Services, Inc. reported strong financial results for the fiscal year ended December 31, 2025, demonstrating solid operational execution. The company generated Net Sales of $3.07 billion, resulting in a Gross Profit of $1.10 billion. Operating Profit reached $584.9 million, supported by disciplined cost management despite significant R&D and SG&A investments. Net Income totaled $493.7 million, translating to Basic and Diluted Earnings Per Share of $7.00. The balance sheet remains robust with Total Assets of $4.27 billion and Total Equity of $3.18 billion. Cash generation was exceptional, with Net Cash Provided by Operating Activities totaling $754.8 million. After Capital Expenditures of $285.9 million, the company achieved significant Free Cash Flow. The firm returned substantial capital to shareholders through $61.2 million in dividend payments and $134.0 million in share repurchases, while maintaining a conservative Long-Term Debt balance of $202.8 million.
For the fiscal year ended December 31, 2025, West Pharmaceutical Services, Inc. delivered solid financial performance. The company reported Net Sales of $3.07 billion and Cost of Goods and Services Sold of $1.97 billion, resulting in a Gross Profit of $1.10 billion. Operating Profit stood at $584.9 million, after accounting for Research and Development expenses of $74.3 million and Selling, General and Administrative expenses of $393.6 million. Net Income reached $493.7 million, supported by Equity in Net Income of Affiliated Companies of $14.4M. Basic and Diluted Earnings Per Share were both reported at $7.00, based on weighted average shares outstanding of 72.3 million and 72.7 million, respectively. The effective tax rate was approximately 20.2%.
The company reported total Net Sales of $3.07 billion for the fiscal year 2025. The document provided does not contain a detailed breakdown of revenue by specific operating segments, geographic regions, or product lines. Consequently, a granular analysis of specific growth drivers or regional mix cannot be determined from the provided XBRL data or document text. Revenue generation appears to be driven by the core business operations reflected in the consolidated figures.
West Pharmaceutical Services maintained healthy profitability metrics. The Gross Margin was approximately 35.8% ($1.10B / $3.07B). Operating Margin was approximately 19.0% ($584.9M / $3.07B). The cost structure included significant investments in R&D ($74.3M) and SG&A ($393.6M). Other Expense provided a benefit of $51.2M to operating profit. Interest Income of $17.5M exceeded Interest Expense of $500K, contributing to the pre-tax income of $600.9M. Net Income Margin was approximately 16.1%.
The company demonstrated strong cash generation capabilities. Net Cash Provided by Operating Activities was $754.8M. Capital Expenditures totaled $285.9M, resulting in a Free Cash Flow of approximately $468.9M. The Balance Sheet shows Total Assets of $4.27B, including Cash and Cash Equivalents of $791.3M. Total Liabilities were $1.09B, with Long-Term Debt at a conservative $202.8M. Total Equity was $3.18B, supported by Retained Earnings of $4.37B. The company returned $195.2M to shareholders via dividends and buybacks.
The provided document text and XBRL data do not contain specific forward-looking statements, management guidance, or strategic priorities regarding future fiscal years. Information regarding risk factors or specific operational outlooks for 2026 was not included in the source material provided for this analysis. Therefore, future expectations cannot be assessed from the current input.